Prognostic impact of biomarkers in PMBCL: rationale for early integration of immune checkpoint inhibitors.

Explor Target Antitumor Ther · 2025 · PMC12098338 · PMID 40416849

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

The addition of nivolumab demonstrated a clear trend toward improved OS at 36 months, with survival rates of 86% (95% CI: 63–100) in the nivolumab group compared to 44% (95% CI: 28–68) in the chemotherapy-only group ( Figure 7 ).

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.